Siedlecki, Jakob
Klaas, Julian
Keidel, Leonie
Asani, Ben
Schiefelbein, Johannes
Knebel, Dominik
Luft, Nikolaus
Priglinger, Siegfried G.
Schworm, Benedikt
Article History
Received: 14 September 2022
Revised: 17 March 2023
Accepted: 5 April 2023
First Online: 8 May 2023
Competing interests
: No author reports any financial interest relevant to this study. Jakob Siedlecki received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH, Allergan GmbH and Heidelberg Engineering GmbH. JS received personal consultation fees from Bayer AG, Novartis Pharma GmbH, Allergan GmbH and Apellis Pharmaceuticals. BA received previous speaker fees from Novartis Pharma GmbH. LFK received income from honoraria as a lecturer from Recordati Pharma GmbH. NL received income from honoraria as a lecturer from Alcon Laboratories Inc., NIDEK Co. Ltd and CenterVue SpA. SP received previous speaker fees and/or travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharma GmbH and Allergan GmbH. BS received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation.